Were the Mesa Laboratories (MLAB) CAO’s share sales made under a trading plan?

Yes. A footnote explains that the 442 shares of common stock were sold to cover taxes on RSU and PSU vesting and that the transaction was executed under a 10b-1 trading plan established in advance.

Mesa Labs CAO sells 442 shares after RSU vesting

Mesa Laboratories CAO Lyndsey Elizabeth Crennen reported a mix of equity compensation events and a small tax-related share sale.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Mesa Laboratories CAO Lyndsey Elizabeth Crennen reported a mix of equity compensation events and a small tax-related share sale. On June 18, 2026, she exercised restricted stock units and performance share units for a total of 726 shares of common stock and received a 263-share grant, all as direct holdings. A subsequent sale of 442 shares of common stock on June 22, 2026 at $89.502 per share was executed to cover taxes related to the June 18, 2026 vesting of RSUs and PSUs and occurred under a 10b-1 plan, according to the footnotes. Following these transactions, she directly holds 2,020 shares of Mesa Laboratories common stock.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 8 txns

Insider Crennen Lyndsey Elizabeth

Role CAO

Sold 442 shs ($40K)

Approx. gross sale proceeds $40K

Approx. exercise cost $0.00

Type	Security	Shares	Price	Value
Sale	Common Stock	442	$89.502	$40K
Exercise	Restricted Stock Unit - 1	125	$0.00	$0.00
Exercise	Restricted Stock Units - 2	233	$0.00	$0.00
Exercise	Restricted Stock Units - 3	368	$0.00	$0.00
Exercise	Common Stock	125	$95.10	$12K
Exercise	Common Stock	233	$95.10	$22K
Exercise	Common Stock	368	$95.10	$35K
Grant/Award	Common Stock	263	$95.10	$25K

Holdings After Transaction: Restricted Stock Unit - 1 — 0 contracts (Direct); Restricted Stock Units - 2 — 232 contracts (Direct); Restricted Stock Units - 3 — 367 contracts (Direct); Common Stock — 2,020 shares (Direct)

Footnotes (7)

F1. Each RSU represents a contingent right to receive one share of the Issuer's common stock
F2. RSUs that vested 1/3 on June 21, 2024 and each of the next two anniversary dates
F3. Not Applicable
F4. RSUs that vest 1/3 on June 18, 2025 and each of the next two anniversary dates
F5. RSUs that vest 1/3 on June 19, 2025 and each of the next 2 anniversary dates
F6. Shares represent common stock of Mesa Labs issued upon release of performance share units issued under the FY24-FY26 performance share unit program
F7. Shares sold to cover taxes related to the vesting of RSUs and PSUs on June 18, 2026. Transaction was executed under a 10b-1 plan.

Key Figures

Shares sold: 442 shares Sale price: $89.502 per share Shares after transactions: 2,020 shares +3 more

6 metrics

Shares sold 442 shares Open-market sale of common stock on June 22, 2026

Sale price $89.502 per share Average price for 442-share sale

Shares after transactions 2,020 shares Direct common stock holdings following reported trades

RSU/PSU shares exercised 726 shares Common stock from RSU and PSU exercises on June 18, 2026

Equity grant 263 shares Grant or award of common stock on June 18, 2026

Net share change from buy/sell -442 shares Net of open-market buys and sells reported

Key Terms

Restricted Stock Units, performance share units, 10b-1 plan, grant, award, or other acquisition, +1 more

5 terms

Restricted Stock Units financial

"Each RSU represents a contingent right to receive one share of the Issuer's common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

10b-1 plan regulatory

"Shares sold to cover taxes related to the vesting of RSUs and PSUs on June 18, 2026. Transaction was executed under a 10b-1 plan."

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Mesa Laboratories (MLAB) CAO Lyndsey Crennen report?

Lyndsey Crennen reported RSU and PSU vesting into Mesa Laboratories common stock, a 263-share equity grant, and a 442-share sale. The sale followed equity awards that converted restricted units into directly held common shares.

How many Mesa Laboratories (MLAB) shares did the CAO sell and at what price?

The CAO sold 442 shares of Mesa Laboratories common stock at an average price of $89.502 per share. This transaction followed recent equity award vesting and was tied to tax obligations from those awards.

Why did the Mesa Laboratories (MLAB) CAO sell 442 shares of stock?

The 442 shares were sold to cover taxes related to the vesting of restricted stock units and performance share units on June 18, 2026. A footnote states this tax-related sale was executed under a 10b-1 trading plan.

How many Mesa Laboratories (MLAB) shares does the CAO own after these transactions?

After exercising equity awards, receiving a grant, and selling shares for taxes, the CAO directly holds 2,020 shares of Mesa Laboratories common stock. This figure reflects her position immediately following the reported transactions.

What equity awards vested for Mesa Laboratories (MLAB) CAO Lyndsey Crennen?

Restricted stock units and performance share units vested into 726 shares of Mesa Laboratories common stock on June 18, 2026. Footnotes note these RSUs vest in thirds on specified anniversary dates under the company’s equity programs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/23/2026 - 01:34 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Crennen Lyndsey Elizabeth

(Last)

(First)

(Middle)

2850 S CLARKSON CIRCLE

(Street)

ENGLEWOOD

COLORADO

80113

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MESA LABORATORIES INC /CO/ [ MLAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CAO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/18/2026		M		125	A	$95.1	1,598	D
Common Stock	06/18/2026		M		233	A	$95.1	1,831	D
Common Stock	06/18/2026		M		368	A	$95.1	2,199	D
Common Stock	06/18/2026		A		263⁽⁶⁾	A	$95.1	2,462	D
Common Stock	06/22/2026		S		442⁽⁷⁾	D	$89.502	2,020	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit - 1	⁽¹⁾	06/18/2026		M			125	06/21/2024⁽²⁾	⁽³⁾	Common Stock	125	$0	0	D
Restricted Stock Units - 2	⁽¹⁾	06/18/2026		M			233	06/18/2025⁽⁴⁾	⁽³⁾	Common Stock	233	$0	232	D
Restricted Stock Units - 3	⁽¹⁾	06/18/2026		M			368	06/19/2025⁽⁵⁾	⁽³⁾	Common Stock	368	$0	367	D

Explanation of Responses:

1. Each RSU represents a contingent right to receive one share of the Issuer's common stock

2. RSUs that vested 1/3 on June 21, 2024 and each of the next two anniversary dates

3. Not Applicable

4. RSUs that vest 1/3 on June 18, 2025 and each of the next two anniversary dates

5. RSUs that vest 1/3 on June 19, 2025 and each of the next 2 anniversary dates

6. Shares represent common stock of Mesa Labs issued upon release of performance share units issued under the FY24-FY26 performance share unit program

7. Shares sold to cover taxes related to the vesting of RSUs and PSUs on June 18, 2026. Transaction was executed under a 10b-1 plan.

	John Sakys under Power of Attorney by Lyndsey Crennen	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR